Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
← catalyst calendarNCT06810544 · readout in 224 d
Sponsored by Tango Therapeutics, Inc. (industry) · TNGX — their whole pipeline →. With Eli Lilly and Company.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
191estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-24 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non Small Cell Lung Cancer
- Glioma Glioblastoma Multiforme
- Glioma, Malignant
- Solid Tumor
- Non-Small Cell Adenocarcinoma
- Lung Cancer
- Brain Tumor
Interventions
- Drug: TNG456
- Drug: abemaciclib — also filed as Verzenio
Primary outcomes
what the primary-completion date above is the date OFPhase 1 Maximum Tolerated Dose
measured 21 days
Phase 2 Anti-neoplastic Activity Single Agent
measured 18 weeks
Phase 2 Anti-neoplastic Activity Combination Treatment
measured 18 weeks
Permalink · TNGX's whole pipeline · Catalyst calendar · Every registered study · What changed